We are live on
!
Find out more
HM
HealthCor Management Portfolio holdings
AUM
$109M
1-Year Est. Return
10.64%
This Fund
S&P 500
This Quarter
Est. Return
+33.19%
1 Year Est. Return
+10.64%
3 Year Est. Return
+50.22%
5 Year Est. Return
+140.3%
10 Year Est. Return
–
AUM
$2.8B
AUM Growth
+$158M
(+6%)
Cap. Flow
-$258M
Cap. Flow
% of AUM
-9.21%
Top 10 Holdings %
Top 10 Hldgs %
41.71%
Holding
75
New
23
Increased
16
Reduced
15
Closed
19
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
Regeneron Pharmaceuticals
REGN
|
+$125M |
| 2 |
Teleflex
TFX
|
+$107M |
| 3 |
HOLX
Hologic
HOLX
|
+$82.4M |
| 4 |
Envista
NVST
|
+$72.4M |
| 5 |
Labcorp
LH
|
+$63.8M |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
Vertex Pharmaceuticals
VRTX
|
+$124M |
| 2 |
Edwards Lifesciences
EW
|
+$115M |
| 3 |
Baxter International
BAX
|
+$90.3M |
| 4 |
Merck
MRK
|
+$88.2M |
| 5 |
CVRS
CORINDUS VASCULAR ROBOTICS, INC
CVRS
|
+$85.5M |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Healthcare | 92.07% |
| 2 | Technology | 1.67% |
| 3 | Industrials | 0.49% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | |
|---|---|---|---|---|---|---|
|
1
Labcorp
LH
$25.9B
| $144M | 5.15% |
992,776
+441,645
| +80% | +$63.8M |
|
|
2
Regeneron Pharmaceuticals
REGN
$76B
| $140M | 4.99% |
+372,770
| New | +$125M |
|
|
NVRO
3
DELISTED
NEVRO CORP.
NVRO
| $138M | 4.91% |
1,170,080
+216,260
| +23% | +$21.4M |
|
|
HOLX
4
DELISTED
Hologic
HOLX
| $129M | 4.59% |
2,464,040
+1,654,470
| +204% | +$82.4M |
|
|
5
Teleflex
TFX
$5.86B
| $117M | 4.16% |
+309,620
| New | +$107M |
|
6
HCA Healthcare
HCA
$85.7B
| $109M | 3.88% |
736,670
+329,440
| +81% | +$44.2M |
|
7
Johnson & Johnson
JNJ
$617B
| $100M | 3.58% |
687,960
+344,420
| +100% | +$46.7M |
|
8
Madrigal Pharmaceuticals
MDGL
$11.4B
| $99.2M | 3.54% |
1,088,310
+57,090
| +6% | +$5.54M |
|
9
Aurinia Pharmaceuticals
AUPH
$1.93B
| $97.7M | 3.48% |
4,820,330
+3,987,960
| +479% | +$36.7M |
|
10
Medtronic
MDT
$110B
| $96.2M | 3.43% |
847,700
+312,950
| +59% | +$34.3M |
|
11
UnitedHealth
UNH
$383B
| $87.8M | 3.13% |
298,720
-94,810
| -24% | -$24.8M |
|
12
Neurocrine Biosciences
NBIX
$18.7B
| $86.7M | 3.09% |
806,864
-686,616
| -46% | -$71.9M |
|
|
13
Envista
NVST
$4.52B
| $84.4M | 3.01% |
2,846,150
+2,546,150
| +849% | +$72.4M |
|
14
Zimmer Biomet
ZBH
$18.4B
| $66.9M | 2.39% |
460,422
-284,649
| -38% | -$39.3M |
|
|
XENT
15
DELISTED
Intersect ENT, Inc
XENT
| $63.2M | 2.25% |
2,536,760
-4,870
| -0.2% | -$98.7K |
|
16
Haemonetics
HAE
$3.85B
| $61.9M | 2.21% |
538,962
+327,292
| +155% | +$39.6M |
|
17
CONMED
CNMD
$1.41B
| $59.9M | 2.14% |
536,020
+109,110
| +26% | +$11.6M |
|
|
BLUE
18
DELISTED
bluebird bio
BLUE
| $59.7M | 2.13% |
52,529
+13,382
| +34% | +$14.5M |
|
19
Becton Dickinson
BDX
$45.6B
| $58.7M | 2.1% |
+221,400
| New | +$55.2M |
|
20
Humana
HUM
$44B
| $57.3M | 2.05% |
156,430
+86,360
| +123% | +$27.4M |
|
21
Bristol-Myers Squibb
BMY
$132B
| $53.9M | 1.92% |
840,000
-277,710
| -25% | -$15.9M |
|
22
Danaher
DHR
$138B
| $50.5M | 1.8% |
371,078
-403,835
| -52% | -$51M |
|
23
Intuitive Surgical
ISRG
$126B
| $49.4M | 1.76% |
250,650
-454,965
| -64% | -$85.2M |
|
|
ABMD
24
DELISTED
Abiomed Inc
ABMD
| $48.9M | 1.74% |
+286,710
| New | +$53.2M |
|
|
25
Merck
MRK
$321B
| $48.5M | 1.73% |
558,804
-1,074,284
| -66% | -$88.2M |
|
Similar funds
IA
EPC
TCMV
SI
HCWM
PC
RF
AWM
HealthCor Management's Q4 2019 Portfolio in Review
As of Q4 2019, HealthCor Management held 75 positions worth $2.8B, up 6% from $2.65B the previous quarter. Its ten largest holdings account for 42% of the portfolio.
HealthCor Management withdrew a net $258M in Q4 2019, closing 19 positions and reducing 15 holdings. Its most notable exit was Baxter International, an estimated $90.3M position sold in full.
By sector, the portfolio is most concentrated in Healthcare at 92% of assets, up from 90% a quarter earlier, followed by Technology and Industrials.
Against the trend, HealthCor Management opened a new position in Regeneron Pharmaceuticals worth $140M.
- HealthCor Management's largest Q4 2019 buy was Regeneron Pharmaceuticals: 372,770 shares worth $140M.
- HealthCor Management added most to Hologic in Q4 2019, an estimated $82.4M increase.
- HealthCor Management's biggest Q4 2019 reduction was Vertex Pharmaceuticals, cutting an estimated $124M.
- HealthCor Management fully exited Baxter International in Q4 2019, selling an estimated $90.3M.
- HealthCor Management's ten largest holdings make up 42% of its $2.8B portfolio in Q4 2019.
- HealthCor Management opened 23 new positions and closed 19 in Q4 2019.
- HealthCor Management's portfolio value rose 6% quarter-over-quarter to $2.8B.
Based on HealthCor Management's 13F filing for Q4 2019, filed 14 Feb 2020.